Of note, for studies assessing OS in different tumor types, the results indicated that promoted BCAR4 levels could significantly predict worse outcome in breast cancer, gastrointestinal cancer, and osteosarcoma with pooled HRs with 95% CIs of 2.44 (1.22, 4.85), 2.04 (1.55, 2.69) and 2.58 (1.38, 4.80) respectively as shown in Figure 3. This evidence concerns the gene BCAR4 and osteosarcoma.